Endonovo Therapeutics, Inc. filed its 10-K on Apr 14, 2022 for the period ending Dec 31, 2021. In this report its auditor, Rose, Snyder & Jacobs, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0027 USD | +10.20% | +8.00% | -68.97% |
2023 | Endonovo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
2023 | Endonovo Therapeutics, Inc 's Sofpulse® Secures Taiwan FDA Approval | CI |
1st Jan change | Capi. | |
---|---|---|
-68.97% | 943K | |
-1.65% | 104B | |
+6.72% | 97.47B | |
+5.71% | 22.25B | |
-12.85% | 21.68B | |
-9.70% | 18.2B | |
-39.98% | 17.02B | |
-10.41% | 16.36B | |
+7.13% | 14.39B | |
+37.44% | 12.37B |
- Stock Market
- Equities
- ENDV Stock
- News Endonovo Therapeutics, Inc.
- Endonovo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt